Insulin-like growth factor-1 (IGF-1), insulin-like growth factor-binding protein-3 (IGFBP-3) and breast cancer risk:observational and Mendelian randomization analyses with ~430,000 women by Murphy, Neil et al.
                          Murphy, N., Knuppel, A., Papadimitriou, N., Martin, R. M., Tsilidis, K.,
Smith Byrne, K., Fensom, G., Perez-Cornago, A., Travis, R. C., Key,
T. J., & Gunter, M. J. (2020). Insulin-like growth factor-1 (IGF-1),
insulin-like growth factor-binding protein-3 (IGFBP-3) and breast
cancer risk: observational and Mendelian randomization analyses with
~430,000 women. Annals of Oncology, 31(5), 641-649.
https://doi.org/10.1016/j.annonc.2020.01.066
Publisher's PDF, also known as Version of record
License (if available):
CC BY-NC-ND
Link to published version (if available):
10.1016/j.annonc.2020.01.066
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via Elsevier at
https://www.sciencedirect.com/science/article/pii/S0923753420360191. Please refer to any applicable terms of
use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the
published version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/
ORIGINAL ARTICLEInsulin-like growth factor-1, insulin-like growth factor-binding protein-3, and
breast cancer risk: observational and Mendelian randomization analyses
with w430 000 womenN. Murphy1*y, A. Knuppel2y, N. Papadimitriou1, R. M. Martin3,4,5, K. K. Tsilidis6,7, K. Smith-Byrne8, G. Fensom2,
A. Perez-Cornago2, R. C. Travis2, T. J. Key2y & M. J. Gunter1y1Section of Nutrition and Metabolism, International Agency for Research on Cancer, Lyon, France; 2Cancer Epidemiology Unit, Nuffield Department of Population
Health, University of Oxford, Oxford; 3MRC Integrative Epidemiology Unit (IEU), Population Health Sciences, Bristol Medical School, University of Bristol, Bristol;
4Bristol Medical School, Department of Population Health Sciences, University of Bristol, Bristol; 5National Institute for Health Research (NIHR) Bristol Biomedical
Research Centre, University Hospitals Bristol NHS Foundation Trust and the University of Bristol, Bristol, UK; 6Department of Hygiene and Epidemiology, University of
Ioannina School of Medicine, Ioannina, Greece; 7Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK; 8Genetic
Epidemiology Group, International Agency for Research on Cancer, Lyon, France
Available online 10 March 2020
Background: Epidemiological evidence supports a positive association between circulating insulin-like growth factor-1
(IGF-1) concentrations and breast cancer risk, but both the magnitude and causality of this relationship are uncertain.
We conducted observational analyses with adjustment for regression dilution bias, and Mendelian randomization (MR)
analyses allowed for causal inference.
Patients and methods: We investigated the associations between circulating IGF-1 concentrations and incident breast
cancer risk in 206 263 women in the UK Biobank. Multivariable hazard ratios (HRs) and 95% confidence intervals (CI)
were estimated using Cox proportional hazards models. HRs were corrected for regression dilution using repeat IGF-1
measures available in a subsample of 6711 women. For the MR analyses, genetic variants associated with circulating
IGF-1 and IGF-binding protein-3 (IGFBP-3) levels were identified and their association with breast cancer was examined
with two-sample MR methods using genome-wide data from 122 977 cases and 105 974 controls.
Results: In the UK Biobank, after a median follow-up of 7.1 years, 4360 incident breast cancer cases occurred. In the
multivariable-adjusted models corrected for regression dilution, higher IGF-1 concentrations were associated with a
greater risk of breast cancer (HR per 5 nmol/l increment of IGF-1 ¼ 1.11, 95% CI ¼ 1.07e1.16). Similar positive
associations were found by follow-up time, menopausal status, body mass index, and other risk factors. In the MR
analyses, a 5 nmol/l increment in genetically-predicted IGF-1 concentration was associated with a greater breast cancer
risk (odds ratio ¼ 1.05, 95% CI ¼ 1.01e1.10; P ¼ 0.02), with a similar effect estimate for estrogen-positive (ERþ)
tumours, but no effect found for estrogen-negative (ER) tumours. Genetically-predicted IGFBP-3 concentrations were
not associatedwith breast cancer risk (odds ratio per 1-standard deviation increment¼ 1.00, 95%CI¼ 0.97e1.04; P¼ 0.98).
Conclusion: Our results support a probable causal relationship between circulating IGF-1 concentrations and breast
cancer, suggesting that interventions targeting the IGF pathway may be beneficial in preventing breast tumorigenesis.
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Insulin-like growth factor-1 (IGF-1) is a polypeptide that has
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Volume 31 - Issue 5 - 2020IGF-1 is bound to IGF bindingproteins,withmost bound to IGF-
binding protein-3 (IGFBP-3).3 In experimental studies, IGFBP-3
has also been shown to not only regulate IGF-1 bioavailability,
but also to have direct inhibitory effects on cell growth.4
Interest in the possible role of IGF-1 in the development of
breast cancer began in the 1980s.5 An early case-control study
reported higher plasma concentrations of IGF-1 in women
with breast cancer than in controls,6 and in the first pro-
spective study, circulating concentrations of IGF-1 were
positively associated with breast cancer risk for premeno-
pausal women, but not postmenopausal women.7 Mosthttps://doi.org/10.1016/j.annonc.2020.01.066 641
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positive association between IGF-1 and breast cancer risk, and
a pooled individual-participant data analysis of 4790 cases
from 17 prospective studies showed that women with rela-
tively high circulating IGF-1 had aw30% higher risk of breast
cancer than women with relatively low circulating IGF-1.
There was no evidence that the association was due to
reverse-causation, varied by menopausal status, or was
attenuated by adjustment for other risk factors including
IGFBP-3, reproductive factors, and body mass index (BMI).8
However, heterogeneity by estrogen receptor (ER) subtype
was found, with the positive association present for estrogen-
positive (ERþ) but not estrogen-negative (ER) tumours. In
addition, this pooled analysis was based on a single IGF-1
measurement for each woman, so risk estimates could have
been influenced by the combined effects of measurement
error and within-person variability, leading to a likely under-
estimation of the true association (regression dilution).8,9
To further examine the possible causal role of IGF-1 in
breast cancer risk, we conducted complementary observa-
tional and Mendelian randomization (MR) analyses. Firstly,
we investigated how prediagnostic circulating concentra-
tions of IGF-1 were related to breast cancer risk in the UK
Biobank study, a large prospective cohort in which a sub-
sample of participants has repeat IGF-1 measures enabling
correction for regression dilution bias. Next, we used a two-
sample MR approach to examine potential causal associa-
tions by combining genetic variants associated with circu-
lating IGF-1 and IGFBP-3 concentrations in genome-wide
association studies (GWAS), and then assessing the associ-
ation of these variants with breast cancer (overall, ERþ, and
ER) risk in a large consortium of 122 977 breast cancer
cases and 105 974 controls.10
METHODS
UK Biobankdobservational analysis
Study participants. The UK Biobank is a prospective cohort
of 502 536 adults aged between 40 and 69 years (229 182
men and 273 474 women) who were recruited between
2006 and 2010.11 The UK Biobank invited w9.2 million
people to participate through postal invitation with a tele-
phone follow-up, with a response rate of 5.7%. All partici-
pants were registered with the UK National Health Service
and lived within w25 miles (40 km) of one of the 22 study
assessment centres. The UK Biobank has approval from the
North West Multi-centre Research Ethics Committee, the
National Information Governance Board for Health and
Social Care in England and Wales, and the Community
Health Index Advisory Group in Scotland. In addition, an
independent Ethics and Governance Council was formed in
2004 to oversee UK Biobank’s continuous adherence to the
Ethics and Governance Framework which was developed for
the study (http://www.ukbiobank.ac.uk/ethics/). All partic-
ipants provided written informed consent at recruitment
and were to be followed up using data-linkage. This
research has been conducted using the UK Biobank
Resource under application numbers 3248 and 24 494.642 https://doi.org/10.1016/j.annonc.2020.01.066During the baseline recruitment visit, participants were
asked to complete a self-administered touchscreen question-
naire, which included questions on sociodemographics
(including age, sex, education, and postcode, used to assign
Townsend deprivation score), health/medical history, and life-
style exposures (including smoking habits, dietary intakes, and
alcohol consumption). At the baseline visit, participants also
underwent physical measurements, including body weight,
height, and waist circumference. Blood samples were collected
from all participants at recruitment, and repeat blood samples
were collected from a subset of w20 000 participants who
re-attended the assessment centre between 2012 and 2013.
Blood samples were centrifuged, and serum stored at 80C.
Exclusions before the onset of analyses were men (n ¼
229 134); women with prevalent cancer (including in situ
breast cancer, but excluding non-malignant skin cancer) at
recruitment (n ¼ 18 560); participants in whom genetic sex
differed from reported gender (n ¼ 121), missing data on
body size measurements (n ¼ 1350); prevalent type-2 dia-
betes or unknown diabetes status at recruitment based on
hospital records and self-report (because diabetes medica-
tions can affect circulating concentrations of IGF-112; n ¼ 10
705); women who reported oral contraceptive and meno-
pausal hormone use at recruitment (because oral estrogens
alter hepatic protein production and change circulating
concentrations of IGF-112; n ¼ 20 988); and participants
without an IGF-1 measurement (n ¼ 15 415). Our analysis
therefore included 206 263 women.
Blood collection and laboratory methods. As part of the UK
Biobank Biomarker Project,13 serum concentrations of IGF-1
(Liaison XL, DiaSorin S.p.A., Italy), testosterone, and sex
hormone binding globulin (SHBG) were determined by a
chemiluminescent immunoassay (DXI 800, Beckman Coulter,
London, UK). The immuno-turbidimetric method (DXI 800)
was used to assay serum high sensitivity C-reactive protein
(CRP) concentrations. Glycated haemoglobin (HbA1c) con-
centrations were determined using the high performance
liquid chromatography (HPLC) Variant II Turbo 2.0 system
(Bio-Rad, Hercules, CA). Full details on assay performance
have been published.13 In summary, average within-
laboratory (total) coefficients of variation for low, medium,
and high internal quality control level samples for each
biomarker ranged from 1.7% to 15.3% (for IGF-1, the co-
efficients of variation ranged from 5.3% to 6.2%).13 A total of
6711 women had IGF-1 concentrations measured in blood
samples collected at both the recruitment and repeat
assessment visit (median of 4 years apart).
Assessment of outcome. Incident cancer cases and cancer
cases first recorded in death certificates within the UK
Biobank cohort were identified through linkage to national
cancer registries and death records. Complete follow-up
was available until 31 March 2016 for England and Wales
and 31 October 2015 for Scotland. Cancer incidence data
were coded using the 10th Revision of the International
Classification of Diseases (ICD-10). Breast cancer was
defined as registration ICD-10: C50.Volume 31 - Issue 5 - 2020
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intervals (CIs) were estimated using Cox proportional haz-
ards models. Age was the primary time variable in all
models. Time at entry was the age at recruitment. Exit time
was the age at whichever of the following came first: breast
cancer diagnosis (n ¼ 4352; 99.8% of all cases), breast
cancer at death without prior diagnosis (n ¼ 8; 0.2% of all
cases), death, or the last date at which follow-up was
considered complete. Models were stratified by age at
recruitment in 5-year categories, Townsend deprivation in-
dex fifths, and region of the recruitment assessment centre.
Deviations from proportionality were assessed using an
analysis of Schoenfeld residuals, with no evidence of non-
proportionality being detected. IGF-1 was modelled on
the continuous scale (per 5 nmol/l) and with participants
grouped into sex-specific fifths of circulating concentrations.
HRs were additionally corrected for regression dilution
using regression dilution ratios obtained from the subsam-
ple of 6711 women with repeated IGF-1 measurement9,14;
to obtain corrected HRs, the log HRs and their standard
errors were divided by the regression dilution ratio for IGF-1
(0.74) and then exponentiated.15 Possible non-linear effects
were modelled using restricted cubic spline models with
five knots placed at Harrell’s default percentiles of circu-
lating IGF-1 concentrations.16
The multivariable model (model 1) was adjusted for a set
of breast cancer risk factors determined a priori, namely
total physical activity, height, alcohol consumption fre-
quency, smoking status and intensity, educational level,
ever use of hormone replacement therapy, parity and age at
first birth, and an interaction between menopausal status
and BMI. We also additionally adjusted the multivariable
models (model 2) for markers of inflammatory, sex hor-
mone, and glycaemic pathways that are known to interre-
late/crosstalk with the IGF system,12 namely CRP,
testosterone, SHBG, and HbA1c. Statistical tests for trend
were calculated using the ordinal fifths of IGF-1 entered
into the model as a continuous variable.
The circulating IGF-1 and breast cancer associations were
further assessed across subgroups of BMI, height, meno-
pausal status at recruitment, ages at blood collection and
diagnosis, follow-up time, smoking status, and circulating
concentrations of CRP, HbA1c, testosterone, and SHBG.
Interaction terms (multiplicative scale) between these vari-
ables and circulating IGF-1 concentrations were included in
separate models, and the statistical significance of the cross-
product terms were evaluated using likelihood ratio tests, or
competing risk for follow-up time and age at diagnosis.
Statistical tests were all two-sided and a P value <0.05
was considered statistically significant. Analyses were con-
ducted using Stata version 14 (StataCorp, College Station, TX).
Mendelian randomization
Genetic determinants of IGF-1 and IGFBP-3. Genetic
markers for circulating IGF-1 and IGFBP-3 concentrations
comprised SNPs identified (P < 5  108) from the largest
GWAS to date.17,18 For IGF-1, this GWAS was of 194 174Volume 31 - Issue 5 - 2020women from the UK Biobank.18 The GWAS analyses of
IGFBP-3 combined data on 18 995 individuals (men and
women) from 13 studies.17 All participants were of Euro-
pean ancestry. From the genome-wide significant variants
identified in these GWAS, we excluded correlated single
nucleotide polymorphisms (SNPs) based on a linkage
disequilibrium level of R2 < 0.01. The instruments for IGF-1
(265 SNPs) and IGFBP-3 (four SNPs) explained 5.2% (F-sta-
tistic value of 40.1) and 6.1% (F-statistic value of 308.4) of
variability in circulating concentrations, respectively. Sum-
mary information on the genetic instruments, and the effect
estimates for each individual SNP with IGF-1 and IGFBP-3
concentrations, are presented in supplementary Tables S1
and S2, available at Annals of Oncology online.
Data on breast cancer. Summary data for the associations
of the IGF-1- and IGFBP-3-related genetic variants with
breast cancer were obtained from a GWAS of 228 951
women [122 977 breast cancer (69 501 ERþ, 21 468 ER)
cases and 105 974 controls] of European ancestry from the
Breast Cancer Association Consortium (BCAC).10 Genotypes
were imputed using the 1000 Genomes Project reference
panel and the regression models adjusted for the first 10
principal components and country or study. Effect estimates
for the association of each individual SNP with breast cancer
are presented in supplementary Table S2, available at
Annals of Oncology online.
Statistical analysis. Two-sample MR analyses using sum-
mary data and an inverse variance weighted approach were
implemented. MR results correspond to an odds ratio (OR)
per 5 nmol/l of genetically-predicted IGF-1 concentration
and per 1-standard deviation (SD) of IGFBP-3. Heterogeneity
of associations across breast cancer subtypes was assessed
by calculating c2 statistics. Cochran’s Q statistics quantified
heterogeneity across the individual SNPs. Sensitivity ana-
lyses were used to check and correct for the presence of
horizontal pleiotropy [i.e. genetic variants influencing the
outcome (breast cancer risk) via a different biological
pathway from the exposures of interest (IGF-1 and IGFBP-
3)]. To evaluate the extent to which directional pleiotropy
(non-balanced horizontal pleiotropy in the MR risk esti-
mates) may have affected the causal estimates for the IGF-1
and breast cancer association, we used an MR-Egger
regression approach.19 We also computed OR estimates
using the complementary weighted-median method that
can give valid MR estimates under the presence of pleiot-
ropy when up to 50% of the included instruments are
invalid.20 The presence of pleiotropy was also assessed
using the MR pleiotropy residual sum and outlier test (MR-
PRESSO). In this, outlying SNPs are excluded from the in-
struments and the effect estimates are reassessed.21 As a
visual evaluation of directional pleiotropy (asymmetry), we
also examined a funnel plot of the effect estimate and
standard error of each SNP within the IGF-1 instrument on
breast cancer risk. For the IGFBP-3 instrument, we con-
ducted leave-one-out analyses to assess the influence of
individual variants on the observed associations. Allhttps://doi.org/10.1016/j.annonc.2020.01.066 643
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Randomization package22 for R (R Foundation for Statistical
Computing, Austria).RESULTS
UK Biobankdobservational analysis
After a median follow-up time of 7.1 years, 4360 incident
breast cancer cases were recorded. Compared with those in
the lowest fifth, participants in the highest circulating IGF-1
fifth were younger, taller, had lower BMI and waist
circumference, and were more likely to be never smokers,
nulliparous, and never users of hormone replacement
therapy (Table 1). In addition, participants in the highest
circulating IGF-1 fifth had lower circulating concentrations
of CRP, HbA1c, and SHBG, with higher circulating concen-
trations of testosterone.
Association between circulating IGF-1 concentrations and
breast cancer risk. Circulating IGF-1 concentrations were
positively associated with breast cancer risk in theTable 1. Characteristics of UK Biobank study participants by fifth of circulating
Characteristic IGF-1 concentrat
1
(n ¼ 41 264)
IGF-1 at baseline, nmol/l 13.8 (2.0)
IGF-1 at follow-up, nmol/l, n ¼ 6711 14.9 (3.5)
Breast cancer, n 836
Age at baseline, years 59.4 (6.9)
BMI, kg/m2 28.3 (6.0)
Waist circumference, cm 87.5 (13.8)
Standing height, cm 161.5 (6.3)
Socioeconomic status (Townsend deprivation index), n (%)
Most deprived fifth 9330 (22.6)
Qualification, n (%)
Professional qualification, college/university degree 21 109 (51.2)
Smoking, n (%)
Never smoker 23 657 (57.3)
Current smoker, 15 cigs/day 1519 (3.7)
Alcohol intake, n (%)
Never 4987 (12.1)
Daily/almost daily 6852 (16.6)
Physical activity, n (%)
<10 METh/week 10 481 (25.4)
60 METh/week 8245 (20.0)
HRT use, n (%)
Never 23 135 (56.1)
Past 18 129 (43.9)
OCP use, n (%)
Never 9642 (23.4)
Past 31 622 (76.6)
Parity, n (%)
Nulliparous 6650 (16.1)
Menopausal status, n (%)
Pre- 4598 (11.1)
Post- 35 099 (85.1)
C-reactive protein, mg/l 3.90 (5.6)
Glycated haemoglobin, mmol/mol 35.9 (4.9)
Testosterone, nmol/l 1.1 (0.6)
Sex hormone binding globulin, nmol/l 64.5 (32.1)
Mean and standard deviation unless specified.
BMI, body mass index; cig, cigarettes; METh, metabolic equivalent hours; HRT, hormone re
644 https://doi.org/10.1016/j.annonc.2020.01.066minimally adjusted model (HR for highest versus lowest
fifth ¼ 1.23, 95% CI ¼ 1.12e1.36; Ptrend < 0.0001)
(Table 2). Statistical adjustment for other breast cancer risk
factors and circulating concentrations of CRP, HbA1c,
testosterone, and SHBG did not materially change the as-
sociation (HR for highest versus lowest fifth ¼ 1.24, 95%
CI ¼ 1.12e1.37; Ptrend < 0.0001). In the restricted cubic
spline model, no deviation from linearity for the relation-
ship between IGF-1 and breast cancer was observed (Pnon-
linear ¼ 0.85). In the continuous multivariable model,
adjusted for circulating concentrations of CRP, HbA1c,
testosterone, and SHBG, a 5 nmol/l increment in IGF-1 was
associated with a higher breast cancer risk (HR ¼ 1.08, 95%
CI ¼ 1.05e1.11). Subsequent correction for regression
dilution bias resulted in a larger positive relationship (HR ¼
1.11, 95% CI ¼ 1.07e1.16). Similar magnitude positive as-
sociations were found according to subgroups of follow-up
time, ages at blood collection and diagnosis, menopausal
status at recruitment, and other breast cancer risk factors
(Pheterogeneity > 0.08) (Figure 1, supplementary Table S3,
available at Annals of Oncology online).insulin-like growth factor-1 (IGF-1) concentrations (N [ 206 263 women)
ions
2 3 4 5
(n ¼ 41 256) (n ¼ 41 239) (n ¼ 41 264) (n ¼ 41 240)
18.0 (0.9) 20.9 (0.8) 23.8 (0.9) 29.4 (3.9)
18.0 (3.3) 20.2 (3.4) 22.4 (3.6) 26.4 (5.2)
818 911 895 900
57.8 (7.4) 56.4 (7.8) 54.9 (8.0) 52.6 (8.2)
27.2 (5.2) 26.7 (4.8) 26.4 (4.5) 26.0 (4.2)
84.9 (12.4) 83.7 (11.7) 82.9 (11.2) 82.0 (10.6)
162.1 (6.2) 162.5 (6.3) 162.9 (6.3) 163.5 (6.3)
8255 (20.0) 7799 (18.9) 7921 (19.2) 7898 (19.2)
22 767 (55.2) 23 763 (57.6) 24 643 (59.7) 25 824 (62.6)
24 223 (58.7) 24 830 (60.2) 25 200 (61.1) 25 806 (62.6)
1450 (3.5) 1310 (3.2) 1367 (3.3) 1352 (3.3)
3712 (9.0) 3354 (8.1) 3239 (7.8) 3128 (7.6)
7313 (17.7) 7036 (17.1) 6666 (16.2) 5586 (13.5)
9546 (23.1) 9314 (22.6) 9216 (22.3) 8921 (21.6)
8544 (20.7) 8379 (20.3) 8383 (20.3) 8142 (19.7)
25 505 (61.8) 27 310 (66.2) 28 846 (69.9) 30 992 (75.2)
15 751 (0.4) 13 929 (33.8) 12 418 (30.1) 10 248 (24.9)
8376 (20.3) 7802 (18.9) 6896 (16.7) 6485 (15.7)
32 880 (79.7) 33 437 (81.1) 34 368 (83.3) 34 755 (84.3)
6854 (16.6) 7551 (18.3) 7816 (18.9) 8709 (21.1)
7382 (17.9) 9642 (23.4) 12 497 (30.3) 16 675 (40.4)
32 049 (77.7) 29 551 (71.7) 26 537 (64.3) 22 041 (53.4)
2.77 (4.2) 2.3 (3.6) 2.0 (3.4) 1.65 (3.1)
35.4 (4.2) 35.1 (4.1) 34.9 (4.0) 34.6 (3.9)
1.1 (0.6) 1.1 (0.6) 1.2 (0.6) 1.2 (0.7)
62.1 (28.7) 60.9 (27.3) 59.7 (26.3) 57.2 (25.1)
placement therapy; OCP, oral contraceptive pill.
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Table 2. Risk (hazard ratios) of breast cancer associated with circulating insulin-like growth factor-1 (IGF-1) concentrations in the UK Biobank
IGF-1 at baseline (nmol/l) N Cases/participants HR (95% CI) HR (95% CI) HR (95% CI)
Model0 Model1 Model2
Fifths
1 (<16.4) 836/40 428 1 (reference) 1 (reference) 1 (reference)
2 (16.4 to <19.5) 818/40 438 1.00 (0.91e1.10) 1.01 (0.92e1.11) 1.01 (0.91e1.11)
3 (19.5 to <22.3) 911/40 328 1.15 (1.05e1.27) 1.16 (1.06e1.28) 1.15 (1.05e1.27)
4 (22.3 to <25.6) 895/40 369 1.16 (1.06e1.28) 1.18 (1.07e1.30) 1.17 (1.06e1.29)
5 (25.6) 900/40 340 1.23 (1.12e1.36) 1.25 (1.13e1.38) 1.24 (1.12e1.37)
Ptrend <0.0001 <0.0001 <0.0001
Per 5 nmol/l increment 4360/206 263 1.08 (1.05e1.11) 1.08 (1.05e1.11) 1.08 (1.05e1.11)
Per 5 nmol/l increment (adjusted)a 4360/206 263 1.11 (1.07e1.15) 1.11 (1.07e1.15) 1.11 (1.07e1.16)
Model0: minimally adjusted model using age as the underlying time variable and stratified by Townsend deprivation index (fifths), region of the recruitment assessment centre,
and age at recruitment (5-year categories).
Model1: multivariable Cox regression model using age as the underlying time variable and stratified by Townsend deprivation index (fifths), region of the recruitment
assessment centre, and age at recruitment (5-year categories). Models adjusted for total physical activity (<10, 10 to <20, 20 to <40, 40 to <60, 60 metabolic equivalent
hours per week, unknown); height (per 10 cm); alcohol consumption frequency (never, special occasions only, one to three times per month, one to two times per week, three
to four times per week, daily/almost daily, unknown); smoking status and intensity (never, former, current <15 per day, current 15 per day, current intensity unknown,
unknown); educational level (CSEs/O-levels/GCSEs or equivalent, NVQ/HND/HNC/A-levels/AS-levels or equivalent, other professional qualifications, college/university degree,
none of the above, unknown); ever use of hormone replacement therapy (no, yes, unknown); parity, age at first birth (nulliparous; 1e2, <25 years; 1e2, 25e30 years; 1e2,
30 years; 1e2, unknown; 3, <25 years; 3, 25e30 years; 3, 30 years; 3, unknown; unknown); and the interaction between menopausal status and body mass index
(kg/m2).
Model2: Model1 plus additional adjustment for circulating concentrations (fifths, missing/unknown) of C-reactive protein (CRP; mg/l), glycated haemoglobin (HbA1c; mmol/
mol), testosterone (nmol/l), and sex hormone binding globulin (SHBG; nmol/l).
CI, confidence interval; HR, hazard ratio; SD, standard deviation.
a HRs per SD increment were additionally corrected for regression dilution using a regression dilution ratio (0.74) obtained from the subsample of women with repeat IGF-1
measurements.
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Association between genetically-predicted circulating IGF-
1 concentrations and breast cancer risk. In the inverse-
variance weighted model, a 5 nmol/l increment in
genetically-predicted IGF-1 concentrations was associated
with greater breast cancer risk (OR ¼ 1.05, 95% CI ¼ 1.01e
1.10; P ¼ 0.02) (Table 3). IGF-1 was positively associated
with ERþ (OR ¼ 1.06, 95% CI ¼ 1.01e1.11; P ¼ 0.03), but
not ER (OR ¼ 1.02, 95% CI ¼ 0.96e1.08; P ¼ 0.58) tu-
mours (Pheterogeneity ¼ 0.32). Evidence of effect heteroge-
neity (Cochran’s Q P values < 0.0001) was found for all
models. Little evidence of directional pleiotropy for the
breast cancer and ERþ breast cancer models (MR-Egger
intercept P values >0.2) was found, with similar magnitude
effect estimates observed for the weighted median and
lower powered MR-Egger models (Table 3). A similar
pattern of results was found when the MR-PRESSO test
detected outlier SNPs were excluded from the models
(supplementary Table S4, available at Annals of Oncology
online). The funnel plots for the IGF-1 instrument
indicated a symmetric distribution of effect estimates
(supplementary Figure S1, available at Annals of Oncology
online).
Association between genetically-predicted circulating
IGFBP-3 concentrations and breast cancer risk. No associ-
ation was found between genetically-predicted circulating
IGFBP-3 concentrations and breast cancer risk (Table 3). A
similar null result was found for the weighted median, MR-
Egger, and leave-one-out sensitivity analyses (Table 3,
supplementary Table S5, available at Annals of Oncology
online).Volume 31 - Issue 5 - 2020DISCUSSION
In the observational analyses of UK Biobank data, we found
that higher circulating concentrations of IGF-1 were asso-
ciated with greater breast cancer risk. This relationship was
consistent for premenopausal and postmenopausal women
and by follow-up time. Consistent with this finding, in our
MR analyses, we found a positive association between
genetically-predicted IGF-1 concentrations and breast can-
cer risk, with this effect restricted to ERþ tumours. These
results support a probable causal role of the IGF pathway in
ERþ breast cancer development.
The positive association found between circulating IGF-1
concentrations and breast cancer in our UK Biobank
observational analyses was monotonic and consistent with
the result from the Endogenous Hormones and Breast
Cancer Collaborative Group, a pooled analysis that included
4790 breast cancers cases and 9428 matched controls from
17 prospective studies.8 Similar to the pooled analysis, this
positive association did not differ by menopausal status,
follow-up time, and subgroups of other breast cancer risk
factors. Our analysis, which included 4360 incident breast
cancer cases, is the largest single study to examine the IGF-1
and breast cancer relationship. Uniquely, measurements of
circulating IGF-1 and other biomarkers were available in the
full UK Biobank cohort, and we were able to adjust our
multivariable models for other serologic factors related to
both circulating IGF-1 concentrations and breast cancer risk,
namely testosterone, SHBG, CRP, and HbA1c.23e27 The risk
estimates for the IGF-1 and breast cancer relationship were
largely unchanged after multivariable statistical adjustment
for these biomarkers and other established risk factors. A
further unique aspect of our analysis was our correction forhttps://doi.org/10.1016/j.annonc.2020.01.066 645
Figure 1. Subgroup analyses of the association between circulating insulin-like growth factor-1 (IGF-1) concentrations and breast cancer risk in the UK Biobank
(per 5 nmol/l increment).
Multivariable Cox regression model using age as the underlying time variable and stratified by Townsend deprivation index (fifths), region of the recruitment assessment
centre, and age at recruitment (5-year categories). Models adjusted for total physical activity (<10, 10 to <20, 20 to <40, 40 to <60, 60 metabolic equivalent hours
per week, unknown); height (per 10 cm); alcohol consumption frequency (never, special occasions only, one to three times per month, one to two times per week, three
to four times per week, daily/almost daily, unknown); smoking status and intensity (never, former, current <15 per day, current 15 per day, current intensity unknown,
unknown); educational level (CSEs/O-levels/GCSEs or equivalent, NVQ/HND/HNC/A-levels/AS-levels or equivalent, other professional qualifications, college/university
degree, none of the above, unknown); ever use of hormone replacement therapy (no, yes, unknown); parity, age at first birth (nulliparous; 1e2, <25 years; 1e2, 25e30
years; 1e2, 30 years; 1e2, unknown; 3, <25 years; 3, 25e30 years; 3, 30 years; 3, unknown; unknown); the interaction between menopausal status and
body mass index (kg/m2); and circulating concentrations (fifths, missing/unknown) of C-reactive protein (CRP; mg/l), glycated haemoglobin (HbA1c; mmol/mol),
testosterone (nmol/l), and sex hormone binding globulin (SHBG; nmol/l). Median values: height ¼ 162 cm; CRP ¼ 1.3 mg/l; HbA1c ¼ 35.1 mmol/mol; testosterone ¼ 1
nmol/l; SHBG ¼ 56.3 nmol/l. HRs per 5 nmol/l increment were additionally corrected for regression dilution using a regression dilution ratio (0.74) obtained from the
subsample of women with repeat IGF-1 measurements.
CI, confidence interval; HR, hazard ratio.
Annals of Oncology N. Murphy et al.regression dilution bias using the repeat IGF-1 measure-
ments available for 6711 women, thereby mitigating the
combined effects of measurement error and within-person
variability on our risk estimates.9 This correction resulted in646 https://doi.org/10.1016/j.annonc.2020.01.066a strengthening of the positive association, supporting the
likelihood that previous epidemiological studies that relied
on a single measurement of IGF-1 concentrations under-
estimated the strength of the positive association withVolume 31 - Issue 5 - 2020
Table 3. Mendelian randomization estimates between circulating concentrations of insulin-like growth factor-1 (IGF-1) and insulin-like growth factor-binding
protein-3 (IGFBP-3) and risk of breast cancer (N [ 122 977 breast cancer cases and N [ 105 974 controls)
Mendelian randomization (MR)
Inverse-variance-weighted (IVW) Weighted median MR-Egger
OR (95% CI) per 5 nmol/l increment OR (95% CI) per 5 nmol/l increment OR (95% CI) per 5 nmol/l increment
IGF-1 (n [ 265 SNPs)
Breast cancer 1.05 (1.01e1.10) 1.08 (1.03e1.13) 1.12 (1.01e1.25)
Breast cancer, ERþ 1.06 (1.01e1.11) 1.10 (1.04e1.18) 1.12 (1.00e1.26)
Breast cancer, ER 1.02 (0.96e1.08) 1.03 (0.95e1.11) 1.17 (1.02e1.34)
IVW Weighted median MR-Egger
OR (95% CI) per 1-SD increment OR (95% CI) per 1-SD increment OR (95% CI) per 1-SD increment
IGFBP-3 (n [ 4 SNPs)
Breast cancer 1.00 (0.97e1.04) 1.00 (0.96e1.04) 0.95 (0.87e1.03)
Breast cancer, ERþ 1.00 (0.96e1.05) 1.00 (0.95e1.04) 0.92 (0.83e1.02)
Breast cancer, ER 0.98 (0.92e1.04) 0.98 (0.91e1.05) 1.03 (0.88e1.20)
CI, confidence interval; ER, estrogen receptor; OR, odds ratio; SD, standard deviation; SNP, single nucleotide polymorphism.
N. Murphy et al. Annals of Oncologybreast cancer risk. For instance, the Endogenous Hormones
and Breast Cancer Collaborative Group reported an OR of
1.25 (95% CI ¼ 1.13e1.39) for an 80 percentile difference in
IGF-18; while the HR at an equivalent scale in the current UK
Biobank analysis rose from 1.26 (95% CI ¼ 1.15e1.38) to
1.37 (95% CI ¼ 1.21e1.55) after correction for regression
dilution bias.
Observational analyses may be subject to residual con-
founding and reverse causality, making causal inference
challenging. We conducted MR analyses of the associations
between IGF-1, IGFBP-3, and breast cancer risk. MR uses
germline genetic variants as proxies (instrumental variables)
to allow causal inference between a given exposure and
outcome. Unlike traditional observational analyses, MR
analyses should be largely free of confounding and reverse
causality due to the random assortment of alleles at meiosis
and germline genetic variants being fixed at conception,
and thus unaffected by the disease process. For IGF-1, the
MR analysis yielded a positive effect estimate similar to our
observational analysis. This positive effect was only present
for ERþ and not ER breast cancer, a result consistent with
earlier observational8 and laboratory evidence,28 which
suggests that crosstalk from estrogen signalling pathways
may influence the IGF-1 and breast cancer relationship.
The bioavailability of IGF-1 in circulation is partly regu-
lated by IGFBPs, with most bound to IGFBP-3. In addition to
enhancing or inhibiting actions of IGF ligands, in vitro
experimental models suggest that IGFBP-3 can inhibit breast
cancer proliferation and induce apoptosis.4,29 Our MR an-
alyses found no evidence of an association between
genetically-predicted IGFBP-3 concentrations and breast
cancer risk. This result is consistent with the Endogenous
Hormones and Breast Cancer Collaborative Group analysis
that reported a null association for IGFBP-3 concentrations
and breast cancer risk after the multivariable models were
adjusted for circulating IGF-1 concentrations.8 Taken
together, these results provide little evidence of IGFBP-3
having a direct effect, independent of its role in IGF
ligand binding, in breast cancer development.Volume 31 - Issue 5 - 2020A fundamental assumption of MR analyses is that the
genetic instrument should not influence the outcome via a
different biological pathway from the exposure of interest
(horizontal pleiotropy). We conducted various sensitivity
analyses to assess the possible influence of horizontal
pleiotropy on our causal estimates, and our results were
robust to these various tests. The possibility exists, however,
that our results may have been influenced by pleiotropy
from other unmeasured IGF axis components.30 To date, the
only GWAS analyses that have been conducted for com-
ponents of this pathway are for IGF-1 and IGFBP-3, there-
fore the extent of this possible pleiotropy within the IGF
axis is uncertain. Genetic instruments are now required for
other IGF system components to disentangle possible bio-
logical effects of specific ligands and binding proteins in
breast cancer development.
The current study is the largest and most comprehensive
investigation of the role of IGF-1 in breast cancer devel-
opment. A limitation of our observational analysis is that
tumour subtype data are currently unavailable in the UK
Biobank; however, these data were available for our MR
analyses and we found that the positive effect for IGF-1 and
breast cancer was only present for ERþ tumours. For our
MR analyses, we were unable to stratify the analyses by
menopausal status; however, our observational analyses
found no difference in the IGF-1 and breast cancer rela-
tionship between premenopausal and postmenopausal
women. Our use of summary-level data for our MR analyses
meant that we were unable to examine possible non-linear
effects or whether the associations between IGF-1 and
breast cancer differed according to subgroups of other risk
factors (e.g. BMI, alcohol consumption); however, in our
observational analyses, which yielded a similar association
to our MR result, we found a linear association between
IGF-1 and breast cancer, and detected no heterogeneity by
subgroups of other risk factors. Finally, the UK Biobank
participation rate was relatively low (5.7%), which may have
introduced selection bias; however, this low response rate
should not markedly influence etiological associations suchhttps://doi.org/10.1016/j.annonc.2020.01.066 647
Annals of Oncology N. Murphy et al.as those reported in our observational analysis, and breast
cancer incidence rates were similar to the UK national
average.31,32
In conclusion, given that plausible biological mechanisms
have been identified,1,2, our observational and MR results
support a probable causal relationship between circulating
IGF-1 concentrations and breast cancer. This result suggests
that pharmacological or lifestyle interventions targeting the
IGF pathway may be beneficial in preventing breast
tumorigenesis.
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